SequelSEC

RECURSION PHARMACEUTICALS, INC. RXRX

Biological Products, (No Diagnostic Substances) · CIK 0001601830 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$74.68M
Fiscal year ended 2025-12-31
Operating income
-$648.13M
Fiscal year ended 2025-12-31
Free cash flow
-$378.28M
Fiscal year ended 2025-12-31

RECURSION PHARMACEUTICALS, INC. (RXRX) reported revenue of $74.68M and net income of -$644.76M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from RECURSION PHARMACEUTICALS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

RECURSION PHARMACEUTICALS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$74.68M$58.84M$44.58M$39.84M$10.18M$3.96M$2.32M
Cost of revenue$70.95M$45.24M$42.59M$48.28M$0$0Unavailable
Gross profit$3.73M$13.60M$1.99M-$8.43M$10.18M$3.96MUnavailable
Operating income-$648.13M-$479.00M-$350.06M-$245.73M-$182.78M-$84.62M-$62.44M
Net income-$644.76M-$463.66M-$328.07M-$239.48M-$186.48M-$87.01M-$61.88M
Research & development$475.27M$314.42M$241.23M$155.70M$135.27M$63.32M$45.81M
Weighted-average diluted sharesshares 447.45Mshares 274.21Mshares 207.85Mshares 175.54Mshares 125.35Mshares 21.78Mshares 21.57M
Pretax income-$644.90M-$464.79M-$332.13M-$239.48M-$186.48MUnavailableUnavailable
Income tax expense-$136.00K-$1.13M-$4.06M$0$0$0$0
Diluted EPS$-1.44$-1.69$-1.58$-1.36$-1.49$-3.99$-2.87
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$176.59M$178.18M$110.82M$81.60M$57.68M$25.26M$18.95M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

RECURSION PHARMACEUTICALS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$743.29M$594.35M$391.56M$549.91M$285.12M$262.13MUnavailable
Total assets$1.47B$1.45B$653.70M$701.29M$610.34M$298.58MUnavailable
Current assets$812.84M$714.27M$438.14M$569.81M$534.72M$266.44MUnavailable
Total liabilities$343.26M$413.82M$190.26M$215.48M$67.41M$56.56MUnavailable
Current liabilities$147.71M$187.47M$93.17M$100.26M$46.66M$23.10MUnavailable
Total equity incl. NCI$1.13B$1.03B$463.44M$485.81M$542.94M-$206.29M-$124.26M
Temporary (mezzanine) equityUnavailableUnavailable$0$0$0$448.31M$201.11M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable$0$34.00K$156.00KUnavailable
Goodwill$162.16M$148.87M$52.06M$801.00K$801.00K$801.00KUnavailable
Long-term debt$9.56M$19.02M$1.10MUnavailable$723.00KUnavailableUnavailable
Accounts payable$18.12M$21.61M$3.95M$4.59M$2.82M$1.07MUnavailable

Cash flow

RECURSION PHARMACEUTICALS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$371.81M-$359.17M-$287.78M-$83.52M-$158.61M-$45.40M-$57.04M
Capital expenditures$6.47M$13.70M$11.96M$37.06M$39.80M$5.83M$3.91M
Investing cash flow-$16.87M$260.06M-$10.23M$193.25M-$271.74M-$8.74M-$3.91M
Financing cash flow$521.53M$304.12M$140.13M$154.34M$458.54M$246.14M$120.41M
Net change in cash$150.90M$201.60M-$157.69M$263.76M$28.18M$192.00M$59.46M
Stock-based compensation$111.22M$81.69M$53.50M$27.91M$14.84M$4.29M$1.38M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$83.70M$36.49M$24.40M$11.76M$8.40M$3.94M$2.49M

Derived

RECURSION PHARMACEUTICALS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flow-$378.28M-$372.87M-$299.74M-$120.58M-$198.41M-$51.23M-$60.95M
Gross margin5.0%23.1%4.5%-21.2%100.0%100.0%Unavailable
Operating margin-867.9%-814.1%-785.3%-616.7%-1795.8%-2135.7%-2692.6%
FCF margin-506.5%-633.7%-672.4%-302.6%-1949.4%-1293.0%-2628.4%
SBC / revenue148.9%138.8%120.0%70.0%145.8%108.3%59.7%
Current ratio5.50x3.81x4.70x5.68x11.46x11.53xUnavailable
Revenue YoY growth26.9%32.0%11.9%291.5%156.9%70.8%Unavailable
Net margin-863.4%-788.0%-736.0%-601.0%-1832.2%-2196.0%-2668.3%
R&D / revenue636.4%534.4%541.2%390.8%1329.1%1598.2%1975.4%
CapEx / revenue8.7%23.3%26.8%93.0%391.0%147.2%168.6%
Long-term debt / equity0.01xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RXRX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-25View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-05View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.